ARTICLE | Clinical News
Aflibercept/rinucumab: Phase II data
October 10, 2016 7:00 AM UTC
Top-line data from the double-blind, U.S. and Japanese Phase II CAPELLA trial in about 500 patients with wet AMD showed that intravitreal injections of 2/1 mg and 2/3 mg REGN2176-3 aflibercept/rinucum...